We are analyzing https://link.springer.com/article/10.1007/bf02034932.

Title:
Mechanisms of bleomycin-induced lung damage | Archives of Toxicology
Description:
Bleomycins are a family of compounds produced byStreptomyces verticillis. They have potent tumour killing properties which have given them an important place in cancer chemotherapy. They cause little marrow suppression, but pulmonary toxicity is a major adverse effect. The mechanisms of cell toxicity are well described based on in vitro experiments on DNA. The bleomycin molecule has two main structural components; a bithiazole component which partially intercalates into the DNA helix, parting the strands, as well as pyrimidine and imidazole structures, which bind iron and oxygen forming an activated complex capable of releasing damaging oxidants in close proximity to the polynucleotide chains of DNA. This may lead to chain scission or structural modifications leading to release of free bases or their propenal derivatives. The mechanisms are well described based on in vitro experiments on DNA, but how they relate to intact cells in whole animals is more tenuous. Bleomycin is able to cause cell damage independent from its effect on DNA by inducing lipid peroxidation. This may be particularly important in the lung and in part account for its ability to cause alveolar cell damage and subsequent pulmonary inflammation. The lung injury seen following bleomycin comprises an interstitial oedema with an influx of inflammatory and immune cells. This may lead to the development of pulmonary fibrosis, characterized by enhanced production and deposition of collagen and other matrix components. Several polypeptide mediators capable of stimulating fibroblasts replication or excessive collagen deposition have been implicated in this, but the precise role of these in bleomycin-induced fibrosis is yet to be demonstrated. Current therapy for bleomycin-induced lung damage is inadequate, with corticosteroids most often used. Given the mechanism of action described above, antioxidants and iron chelators might be beneficial. Although, studies to date are equivocal and there is insufficient evidence to promote their use clinically. Novel drugs are currently being developed and it is hoped these may be more useful.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, pubmed, bleomycin, article, pulmonary, cancer, dna, cells, human, lung, res, chem, cell, growth, biol, fibrosis, induced, rev, dis, med, respir, damage, toxicity, bleomycininduced, collagen, biochem, factor, umezawa, oxygen, laurent, biochemistry, exp, effect, iron, biophys, eds, mechanism, inhibition, degradation, strand, complex, scission, production, commun, int, horwitz, formation, antibiot, mechanisms,

Topics {✒️}

c-g-c-g-c month download article/chapter systemic n-acetyl cystein c-sis proto-oncogene nadph-cytochrome p-450 reductase platelet-derived growth factor pulmonary veno-occlusive disease heparin-sepharose affinity chromatography iron-bleomycin-deoxyribonucleic acid system bleomycin-induced lung damage x-ray structure determination drug-induced pulmonary fibrosis bleomycin-induced lung fibrosis bleomycin-induced pulmonary edema bleomycin-induced pulmonary fibrosis 5′-gt-3′ binding site endothelial cell proliferation dna damage induced full article pdf n-acetyl cysteine cultured human cells alveolar cell damage privacy choices/manage cookies pulmonary fibrosis induced express fibroblast growth lung injury induced collagenase-stimulating factor growth factors derived bleomycin lung damage macrophage-derived factor cartilage catabolic factor fibrin-stabilizing factor human t-lymphocyte cell damage independent bleomycin-induced fibrosis functional bleomycin models cold spring harbor chronic pulmonary inflammation human monocytes exposed pulmonary toxicity induced peptide growth factors acute lung injury siderophore mediated absorption great alveolar cells latent collagenase produced serum free medium dna strand breakage human a-253 cells rheumatoid synovial cells bleomycin c-termini

Questions {❓}

Ward HE, Nicholson A, Berend N (1986b) Does systemic N-acetyl cystein (NAC) protect against bleomycin induced lung injury?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mechanisms of bleomycin-induced lung damage
         description:Bleomycins are a family of compounds produced byStreptomyces verticillis. They have potent tumour killing properties which have given them an important place in cancer chemotherapy. They cause little marrow suppression, but pulmonary toxicity is a major adverse effect. The mechanisms of cell toxicity are well described based on in vitro experiments on DNA. The bleomycin molecule has two main structural components; a bithiazole component which partially intercalates into the DNA helix, parting the strands, as well as pyrimidine and imidazole structures, which bind iron and oxygen forming an activated complex capable of releasing damaging oxidants in close proximity to the polynucleotide chains of DNA. This may lead to chain scission or structural modifications leading to release of free bases or their propenal derivatives. The mechanisms are well described based on in vitro experiments on DNA, but how they relate to intact cells in whole animals is more tenuous. Bleomycin is able to cause cell damage independent from its effect on DNA by inducing lipid peroxidation. This may be particularly important in the lung and in part account for its ability to cause alveolar cell damage and subsequent pulmonary inflammation. The lung injury seen following bleomycin comprises an interstitial oedema with an influx of inflammatory and immune cells. This may lead to the development of pulmonary fibrosis, characterized by enhanced production and deposition of collagen and other matrix components. Several polypeptide mediators capable of stimulating fibroblasts replication or excessive collagen deposition have been implicated in this, but the precise role of these in bleomycin-induced fibrosis is yet to be demonstrated. Current therapy for bleomycin-induced lung damage is inadequate, with corticosteroids most often used. Given the mechanism of action described above, antioxidants and iron chelators might be beneficial. Although, studies to date are equivocal and there is insufficient evidence to promote their use clinically. Novel drugs are currently being developed and it is hoped these may be more useful.
         datePublished:
         dateModified:
         pageStart:81
         pageEnd:94
         sameAs:https://doi.org/10.1007/BF02034932
         keywords:
            Bleomycin
            Lung damage
            Pharmacology/Toxicology
            Occupational Medicine/Industrial Medicine
            Environmental Health
            Biomedicine
            general
         image:
         isPartOf:
            name:Archives of Toxicology
            issn:
               1432-0738
               0340-5761
            volumeNumber:65
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:John Hay
               affiliation:
                     name:University of London
                     address:
                        name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shahriar Shahzeidi
               affiliation:
                     name:University of London
                     address:
                        name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Geoffrey Laurent
               affiliation:
                     name:University of London
                     address:
                        name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mechanisms of bleomycin-induced lung damage
      description:Bleomycins are a family of compounds produced byStreptomyces verticillis. They have potent tumour killing properties which have given them an important place in cancer chemotherapy. They cause little marrow suppression, but pulmonary toxicity is a major adverse effect. The mechanisms of cell toxicity are well described based on in vitro experiments on DNA. The bleomycin molecule has two main structural components; a bithiazole component which partially intercalates into the DNA helix, parting the strands, as well as pyrimidine and imidazole structures, which bind iron and oxygen forming an activated complex capable of releasing damaging oxidants in close proximity to the polynucleotide chains of DNA. This may lead to chain scission or structural modifications leading to release of free bases or their propenal derivatives. The mechanisms are well described based on in vitro experiments on DNA, but how they relate to intact cells in whole animals is more tenuous. Bleomycin is able to cause cell damage independent from its effect on DNA by inducing lipid peroxidation. This may be particularly important in the lung and in part account for its ability to cause alveolar cell damage and subsequent pulmonary inflammation. The lung injury seen following bleomycin comprises an interstitial oedema with an influx of inflammatory and immune cells. This may lead to the development of pulmonary fibrosis, characterized by enhanced production and deposition of collagen and other matrix components. Several polypeptide mediators capable of stimulating fibroblasts replication or excessive collagen deposition have been implicated in this, but the precise role of these in bleomycin-induced fibrosis is yet to be demonstrated. Current therapy for bleomycin-induced lung damage is inadequate, with corticosteroids most often used. Given the mechanism of action described above, antioxidants and iron chelators might be beneficial. Although, studies to date are equivocal and there is insufficient evidence to promote their use clinically. Novel drugs are currently being developed and it is hoped these may be more useful.
      datePublished:
      dateModified:
      pageStart:81
      pageEnd:94
      sameAs:https://doi.org/10.1007/BF02034932
      keywords:
         Bleomycin
         Lung damage
         Pharmacology/Toxicology
         Occupational Medicine/Industrial Medicine
         Environmental Health
         Biomedicine
         general
      image:
      isPartOf:
         name:Archives of Toxicology
         issn:
            1432-0738
            0340-5761
         volumeNumber:65
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:John Hay
            affiliation:
                  name:University of London
                  address:
                     name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shahriar Shahzeidi
            affiliation:
                  name:University of London
                  address:
                     name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Geoffrey Laurent
            affiliation:
                  name:University of London
                  address:
                     name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Archives of Toxicology
      issn:
         1432-0738
         0340-5761
      volumeNumber:65
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of London
      address:
         name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
         type:PostalAddress
      name:University of London
      address:
         name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
         type:PostalAddress
      name:University of London
      address:
         name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:John Hay
      affiliation:
            name:University of London
            address:
               name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
               type:PostalAddress
            type:Organization
      name:Shahriar Shahzeidi
      affiliation:
            name:University of London
            address:
               name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
               type:PostalAddress
            type:Organization
      name:Geoffrey Laurent
      affiliation:
            name:University of London
            address:
               name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
      name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
      name:Biochemistry Unit, Department of Thoracic Medicine, National Heart and Lung Institute, University of London, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(404)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.12s.

LINK . SPRINGER . COM {}